U.S. markets close in 6 hours 1 minute
  • S&P 500

    3,288.45
    -21.66 (-0.65%)
     
  • Dow 30

    26,523.25
    -135.86 (-0.51%)
     
  • Nasdaq

    11,034.33
    -151.26 (-1.35%)
     
  • Russell 2000

    1,553.21
    -8.36 (-0.54%)
     
  • Crude Oil

    35.65
    -0.52 (-1.44%)
     
  • Gold

    1,886.30
    +18.30 (+0.98%)
     
  • Silver

    23.67
    +0.31 (+1.33%)
     
  • EUR/USD

    1.1692
    +0.0014 (+0.12%)
     
  • 10-Yr Bond

    0.8380
    +0.0030 (+0.36%)
     
  • GBP/USD

    1.2966
    +0.0043 (+0.33%)
     
  • USD/JPY

    104.5050
    -0.1050 (-0.10%)
     
  • BTC-USD

    13,253.40
    -45.45 (-0.34%)
     
  • CMC Crypto 200

    259.41
    -4.23 (-1.60%)
     
  • FTSE 100

    5,577.48
    -4.27 (-0.08%)
     
  • Nikkei 225

    22,977.13
    -354.81 (-1.52%)
     

Xencor to Present Initial Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium

·3 mins read

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that initial data from its ongoing Phase 1 dose-escalation study of tidutamab (XmAb®18087), an SSTR2 x CD3 bispecific antibody, in patients with neuroendocrine tumors (NETs) will be presented during the upcoming North American Neuroendocrine Tumor Society’s 2020 Multidisciplinary NET Medical Virtual Symposium.

Presentation Details

An abstract (#111) and a poster with initial data from the study will become available in the NANETS Virtual Poster Hall on Friday, October 2, 2020 at 9:00 a.m. ET.

The abstract was also selected to be presented in an oral session:

  • Title: Preliminary Safety, PK/PD, and Antitumor Activity of XmAb18087, an SSTR2 x CD3 Bispecific Antibody, in Patients with Advanced Neuroendocrine Tumors

  • Presenter: Bassel El-Rayes, M.D., Professor and Vice Chair for Clinical Research of the Department of Hematology and Medical Oncology at Emory University School of Medicine, as well as Director of the Gastrointestinal Oncology Program at Winship Cancer Institute

  • Session: Clinical Abstracts

  • Date & Time: Saturday, October 3, 2020, 2:00 p.m. ET

About Tidutamab

Tidutamab (XmAb®18087) is a tumor-targeted bispecific antibody that contains both an SSTR2 binding domain and a T-cell binding domain (CD3). An XmAb® bispecific Fc domain serves as the scaffold for the two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on tidutamab. SSTR2 (somatostatin receptor 2) is an antigen highly expressed on some solid tumors, and engagement of CD3 by tidutamab activates T cells for highly potent and targeted killing of SSTR2-expressing tumor cells. Tidutamab is being evaluated in an ongoing Phase 1 study, which is enrolling patients with neuroendocrine tumors (NETs) and gastrointestinal stromal tumors (GISTs).

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Currently, 18 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of applicable securities laws, including, but not limited to the timing, expectations and success of clinical trials, product candidates and Xencor's research and development programs. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks described in Xencor's public securities filings. For a discussion of these and other factors, please refer to Xencor's annual report on Form 10-K for the year ended December 31, 2019 as well as Xencor's subsequent filings with the Securities and Exchange Commission. All forward-looking statements are based on Xencor's current information and belief as well as assumptions made by Xencor. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Xencor undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200909005397/en/

Contacts

Charles Liles
626-737-8118
cliles@xencor.com

Media Contact
Jason I. Spark
Canale Communications
619-849-6005
jason@canalecomm.com